The industry’s leading scalable electroporation technology for high yield transient expression of complex proteins, vaccines and biologics.

• Rapidly transfect from 75 thousand to 20 billion cells
• High efficiency with flexible media strategies deliver significant cost savings
• Improved yields, at scale, can decrease development timelines
• Proprietary Flow Electroporation™ Technology
• Faster production of stable clones
• ISO-certified, and CE-marked